Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel + lobaplatin induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR1900025080Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and lobaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
paclitaxellobaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900025080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025080.